Selected Publications

Academic Article

Year Title Altmetric
2022 Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate 2022
2022 Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I studyBMC Cancer.  22. 2022
2022 Plasma and cellular ivacaftor concentrations in patients with cystic fibrosisPediatric pulmonology. Supplement.  57:2745-2753. 2022
2022 Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters NeurobehaviorFrontiers in Pharmacology.  13. 2022
2022 Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trialLancet HIV.  9:e332-e340. 2022
2022 Time to Viral Rebound After Interruption of Modern Antiretroviral TherapiesClinical Infectious Diseases.  74:865-870. 2022
2022 Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosisJournal of Cystic Fibrosis.  21:e8-e10. 2022
2021 An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancerBreast Cancer Research.  23. 2021
2021 A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy.Journal of Infectious Diseases.  224:648-656. 2021
2021 A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons with HIV-1 on Suppressive Antiretroviral TherapyJournal of Infectious Diseases.  224:648-656. 2021
2021 Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic DevelopmentClinical Pharmacology and Therapeutics.  110:64-68. 2021
2021 Implications of Efavirenz Pharmacogenetics When Switching from Efavirenz- to Dolutegravir-containing Antiretroviral RegimensClinical Infectious Diseases.  72:1820-1822. 2021
2021 Pharmacokinetics and safety of maraviroc in neonatesAIDS.  35:419-427. 2021
2021 Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living with Human Immunodeficiency Virus and Receiving Rifampin for TuberculosisJournal of the Pediatric Infectious Diseases Society.  10:201-204. 2021
2020 Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097 2020
2020 Genital shedding of human immunodeficiency virus Type-1 (HIV) when antiretroviral therapy suppresses HIV replication in the plasmaJournal of Infectious Diseases.  222:777-786. 2020
2020 Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapyJournal of Cystic Fibrosis.  19:742-745. 2020
2020 Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate CancerCells.  9. 2020
2020 Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110) 2020
2020 Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: Protocol for a randomised, double-blind,placebo-controlled, treatment trialBMJ Open.  10. 2020
2020 Advances in the development of therapeutics for cytomegalovirus infectionsJournal of Infectious Diseases.  221:32-44. 2020
2020 Long-term safety and efficacy of dolutegravir in treatment-experienced adolescents with human immunodeficiency virus infection: Results of the impaact p1093 studyJournal of the Pediatric Infectious Diseases Society.  9:159-165. 2020
2019 Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110 2019
2019 Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosisAIDS.  33:2197-2203. 2019
2019 Maternal–Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing 2019
2019 Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210AIDS Research and Human Retroviruses.  35:691-697. 2019
2019 Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: Week 48 outcomes from ACTG 5353Journal of Antimicrobial Chemotherapy.  74:1376-1380. 2019
2019 Race/ethnicity and protease inhibitor use influence plasma tenofovir exposure in adults living with HIV-1 in AIDS Clinical Trials Group Study A5202Antimicrobial Agents and Chemotherapy.  63. 2019
2019 Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical TrialBiology of Blood and Marrow Transplantation.  25:515-521. 2019
2019 Transdermal Delivery of Enfuvirtide in a Porcine Model Using a Low-Frequency, Low-Power Ultrasound Transducer PatchUltrasound in Medicine and Biology.  45:513-525. 2019
2018 Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trialLancet HIV.  5:e715-e722. 2018
2018 The control of HIV after antiretroviral medication pause (CHAMP) study: Posttreatment controllers identified from 14 clinical studiesJournal of Infectious Diseases.  218:1954-1963. 2018
2018 Randomized clinical trial to assess the impact of the broadly neutralizing HIV-1 monoclonal antibody VRC01 on HIV-1 persistence in individuals on effective ARTOpen Forum Infectious Diseases.  5. 2018
2018 HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollersJournal of Clinical Investigation.  128:4074-4085. 2018
2018 Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activationAIDS.  32:1389-1401. 2018
2018 ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants with HIV-1 RNA <500000 Copies/mLClinical Infectious Diseases.  66:1689-1697. 2018
2018 Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized TrialClinical Infectious Diseases.  66:1794-1797. 2018
2018 Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducerPediatric pulmonology. Supplement.  53:E6-E8. 2018
2018 Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIVAIDS.  32:729-737. 2018
2018 Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse eventsPharmacogenetics and Genomics.  28:179-187. 2018
2018 Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIVAIDS.  32:2507-2516. 2018
2018 HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapyAIDS.  32:2151-2159. 2018
2017 Pharmacokinetics of darunavir/ritonavir with etravirine both twice daily in human immunodeficiency virus-infected adolescents and young adultsJournal of the Pediatric Infectious Diseases Society.  6:294-296. 2017
2017 Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzeeRetrovirology.  14. 2017
2017 Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapyJournal of Infectious Diseases.  215:1725-1733. 2017
2017 Current status of the pharmacokinetics and pharmacodynamics of HIV-1 entry inhibitors and HIV therapyCurrent Drug Metabolism.  18:769-781. 2017
2017 Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/p21WAF1/CIP1 and p27KIP1 pathwayOncotarget.  8:17216-17228. 2017
2016 Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults 2016
2016 Rilpivirine pharmacokinetics without and with darunavir/ritonavir once daily in adolescents and young adults 2016
2016 Pharmacokinetics of once-daily darunavir/ ritonavir with and without etravirine in human immunodeficiency virus-infected children, adolescents, and young adultsJournal of the Pediatric Infectious Diseases Society.  5:131-137. 2016
2016 Pilot evaluation of ivacaftor for chronic bronchitis 2016
2016 Cerebrospinal fluid concentrations of tenofovir and emtricitabine in the setting of HIV-1 protease inhibitor-based regimensJournal of Clinical Pharmacology.  56:492-496. 2016
2015 Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type-1-infected children 4 weeks to 2 years of ageJournal of the Pediatric Infectious Diseases Society.  4:e76-e83. 2015
2015 A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsisJournal of the Pediatric Infectious Diseases Society.  5:53-62. 2015
2015 Less Bone Loss with Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 StudyClinical Infectious Diseases.  61:1179-1188. 2015
2015 Valganciclovir for Symptomatic Congenital Cytomegalovirus DiseaseObstetrical and Gynecological Survey.  70:489-490. 2015
2015 Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202Pharmacogenetics and Genomics.  25:450-461. 2015
2015 Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of ageJournal of Clinical Pharmacology.  55:748-756. 2015
2015 The authors replyNew England Journal of Medicine.  372:2463. 2015
2015 Perinatal pharmacokinetics of azithromycin for cesarean prophylaxisAmerican Journal of Obstetrics and Gynecology.  212:812.e1-812.e6. 2015
2015 Valganciclovir for symptomatic congenital cytomegalovirus diseaseNew England Journal of Medicine.  372:933-943. 2015
2015 Helicase-primase as a target of new therapies for herpes simplex virus infectionsClinical Pharmacology and Therapeutics.  97:66-78. 2015
2015 Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patientsAIDS.  29:1113-1115. 2015
2015 Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents : Forty-eight-week results from IMPAACT P1093 2015
2014 Pharmacokinetic Enhancers in HIV TherapeuticsClinical Pharmacokinetics.  53:865-872. 2014
2014 Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-Naïve patientsClinical Pharmacokinetics.  53:361-371. 2014
2014 Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapyPLoS One.  9. 2014
2014 La utilización del software educativo en el desarrollo de la educación ambiental en Cuba 2014
2014 Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 yearsClinical Infectious Diseases.  58:413-422. 2014
2014 A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma 2014
2014 Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrationsJournal of Clinical Pharmacology.  54:1063-1071. 2014
2014 Raltegravir pharmacokinetics in neonates following maternal dosing 2014
2014 Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypesJournal of Antimicrobial Chemotherapy.  69:2175-2182. 2014
2014 The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approachClinical Pharmacology and Therapeutics.  96:380-389. 2014
2014 Transplacental transfer of azithromycin and its use for eradicating intra-amniotic ureaplasma infection in a primate modelJournal of Infectious Diseases.  209:898-904. 2014
2013 Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: A single arm pharmacokinetic studyPLoS One.  8. 2013
2013 Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study 2013
2013 Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248Journal of Infectious Diseases.  208:884-891. 2013
2013 Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmissionJournal of Infectious Diseases.  208:662-671. 2013
2013 Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral doseBritish Journal of Clinical Pharmacology.  75:997-1006. 2013
2013 Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenzaJournal of Infectious Diseases.  207:709-720. 2013
2013 The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: A case-control studyJournal of epilepsy.  103:245-253. 2013
2013 Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adultsAIDS.  27:221-225. 2013
2013 Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics.Adolescent Health, Medicine and Therapeutics.  4:79-87. 2013
2013 Uptake of tenofovir and emtricitabine into non-monocytic female genital tract cells with and without hormonal contraceptives.Journal of Experimental Pharmacology.  5:55-64. 2013
2012 Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infectionAIDS.  26:2257-2259. 2012
2012 Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility dataAntimicrobial Agents and Chemotherapy.  56:5938-5945. 2012
2012 Nevirapine exposure with WHO pediatric weight band dosing: Enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experienceAntimicrobial Agents and Chemotherapy.  56:5374-5380. 2012
2012 Oseltamivir dosing in premature infantsJournal of Infectious Diseases.  206:847-850. 2012
2012 A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS modelPLoS Pathogens.  8. 2012
2012 Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection 2012
2012 Reply to 'pharmacokinetic concerns related to darunavir/ritonavir plus raltegravir combination therapy trial'AIDS.  26:397-398. 2012
2012 Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variantsPharmacogenetics and Genomics.  22:858-867. 2012
2012 Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate modelAmerican Journal of Obstetrics and Gynecology.  207:475.e1-475.e14. 2012
2012 Tenofovir: Once-daily dosage in the management of HIV infection 2012
2011 Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)AIDS.  25:2113-2122. 2011
2011 Immune activation mediated change in alpha-1-acid glycoprotein: Impact on total and free lopinavir plasma exposureJournal of Clinical Pharmacology.  51:1539-1548. 2011
2011 Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patientsAntimicrobial Agents and Chemotherapy.  55:4290-4294. 2011
2011 A randomized crossover study to determine relative bioequivalence of tenofovir, emtricitabine, and efavirenz (Atripla) fixed-dose combination tablet compared with a compounded oral liquid formulation derived from the tablet 2011
2011 A dynamic Bayesian nonlinear mixed-effects model of HIV response incorporating medication adherence, drug resistance and covariatesAnnals of Applied Statistics.  5:551-577. 2011
2010 Determination of appropriate dosing of influenza drugs in pediatric patientsClinical Pharmacology and Therapeutics.  88:704-707. 2010
2010 Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: An AIDS clinical trials group studyJournal of Infectious Diseases.  202:717-722. 2010
2010 Oseltamivir dosing for influenza infection in premature neonatesJournal of Infectious Diseases.  202:563-566. 2010
2010 Hierarchical Bayesian inference for HIV dynamic differential equation models incorporating multiple treatment factors 2010
2010 Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapyClinical Infectious Diseases.  50:912-919. 2010
2010 A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, ZambiaAIDS.  24:447-455. 2010
2010 The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy.Journal of Clinical Pharmacology.  50:1050-1055. 2010
2009 13C-5-FU breath test current status and future directions: A comprehensive review 2009
2009 Antiretroviral rounds. Happy 50th? Sedation for colonoscopy in HIV-infected patients.AIDS clinical care.  21:45-46. 2009
2009 Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created EqualClinical Infectious Diseases.  48:1138-1151. 2009
2009 Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African AmericansJournal of Infectious Diseases.  199:872-880. 2009
2009 Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir 2009
2009 Pharmacologic aspects of new antiretroviral drugsCurrent HIV/AIDS Reports.  6:43-50. 2009
2009 Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adultsHIV Clinical Trials.  10:181-192. 2009
2009 Electrocardiogram abnormalities with Atazanavir and Lopinavir/RitonavirHIV Clinical Trials.  10:328-336. 2009
2009 Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)HIV Clinical Trials.  10:343-355. 2009
2009 Novel methodology for antiretroviral quantitation in the female genital tractHIV Clinical Trials.  10:193-199. 2009
2009 Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/ emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II)HIV Clinical Trials.  10:160-167. 2009
2009 Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients 2009
2009 Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serumHIV Clinical Trials.  10:41-47. 2009
2008 No residual activity of raltegravir after development of 148 complex mutations in vivoJournal of the International Association of Providers of AIDS Care.  7:281-282. 2008
2008 Pharmacologic aspects of new antiretroviral drugsCurrent Infectious Disease Reports.  10:522-529. 2008
2008 Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugsNature Medicine.  14:762-766. 2008
2008 A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma 2008
2008 Pediatric clinical pharmacology and its implications for antiretroviral drug developmentCurrent Opinion in HIV and AIDS.  3:272-276. 2008
2008 Treatment response in acute/early infection versus advanced AIDS: Equivalent first and second phases of HIV RNA declineAIDS.  22:957-962. 2008
2008 Efavirenz-Based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell countsJournal of Infectious Diseases.  197:1006-1010. 2008
2008 Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: Results of ACTG A5186 2008
2008 Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus diseaseJournal of Infectious Diseases.  197:836-845. 2008
2008 Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjectsJournal of Infectious Diseases.  197:867-870. 2008
2008 Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIVHIV Clinical Trials.  9:91-102. 2008
2008 Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus 2008
2007 Cloning and characterization of recombinant rhesus macaque IL-10/Fcala-ala fusion protein: A potential adjunct for tolerance induction strategiesCytokine.  40:183-192. 2007
2007 Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infantsAntimicrobial Agents and Chemotherapy.  51:4297-4302. 2007
2007 Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapyAntiviral Therapy.  12:981-986. 2007
2007 Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice dailyAntimicrobial Agents and Chemotherapy.  51:3104-3110. 2007
2007 Lopinavir/ritonavir pharmacokinetic profile: Impact of sex and other covariates following a change from twice-daily to once-daily therapyJournal of Clinical Pharmacology.  47:970-977. 2007
2007 Persistence of nevirapine in breast milk after discontinuation of treatmentClinical Infectious Diseases.  45:391-394. 2007
2007 A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS clinical trials group study A5115Antiviral Therapy.  12:531-541. 2007
2007 Development of a sensitive and specific liquid chromatography/mass spectrometry method for the determination of tenofovir in human plasmaRapid Communications in Mass Spectrometry.  21:2087-2094. 2007
2007 Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infantsAntimicrobial Agents and Chemotherapy.  51:2208-2210. 2007
2007 Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulationClinical Pharmacology and Therapeutics.  81:867-872. 2007
2007 Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjectsAIDS.  21:1373-1375. 2007
2007 Pharmacokinetic study of puerarin in rat serum by liquid chromatography tandem mass spectrometryBiomedical Chromatography.  21:410-414. 2007
2007 Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteriaJournal of Pharmacokinetics and Pharmacodynamics.  34:35-55. 2007
2007 Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteersJournal of Clinical Pharmacology.  47:201-208. 2007
2006 Design issues in initial HIV-treatment trials: Focus on ACTG A5095Antiviral Therapy.  11:751-760. 2006
2006 Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: A randomized controlled trialJournal of the American Medical Association.  296:769-781. 2006
2006 Reply to Tong et al. [4]Clinical Infectious Diseases.  43:542-544. 2006
2006 Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: Using viral dynamic models that incorporate drug susceptibility and adherenceJournal of Pharmacokinetics and Pharmacodynamics.  33:399-419. 2006
2006 Tipranavir: A novel nonpeptidic protease inhibitor of HIVClinical Pharmacokinetics.  45:665-682. 2006
2006 Clinical pharmacodynamics of HIV-1 protease inhibitors: Use of inhibitory quotients to optimise pharmacotherapyLancet Infectious Diseases.  6:215-225. 2006
2006 Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An adult AIDS clinical trials group studyClinical Infectious Diseases.  42:401-407. 2006
2006 Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitnessAIDS.  20:223-231. 2006
2006 Field performance of a thin-layer chromatography assay for detection of nevirapine in umbilical cord bloodHIV Clinical Trials.  7:263-269. 2006
2006 Field performance of a thin-layer chromatography assay for detection of nevirapine in umbilical cord blood.HIV Clinical Trials.  7:263-269. 2006
2005 Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individualsACP journal club.  143. 2005
2005 Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359 2005
2005 Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapyAntiviral Therapy.  10:375-392. 2005
2005 Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, ZambiaAIDS.  19:1309-1315. 2005
2005 Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugsAntiviral Therapy.  10:469-477. 2005
2005 Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapyAIDS.  19:1059-1063. 2005
2005 Modeling long-term HIV dynamics and antiretroviral response: Effects of drug potency, pharmacokinetics, adherence, and drug resistance 2005
2005 Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 resultsAIDS.  19:145-152. 2005
2005 Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: Pediatric AIDS Clinical Trials Group Protocol 403 2005
2004 Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group studyAIDS.  18:2391-2400. 2004
2004 Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals 2004
2004 Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tubeHIV Clinical Trials.  5:288-293. 2004
2004 Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjectsJournal of Infectious Diseases.  190:886-893. 2004
2004 Pharmacokinetic enhancement of protease inhibitor therapyClinical Pharmacokinetics.  43:291-310. 2004
2004 Antiretroviral drug content in products from developing countriesClinical Infectious Diseases.  38:1317-1319. 2004
2004 Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infectionNew England Journal of Medicine.  350:1850-1861. 2004
2004 Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settingsAIDS.  18:939-943. 2004
2004 Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials group study 359Journal of Infectious Diseases.  189:1176-1184. 2004
2004 Detection of Nevirapine in Plasma Using Thin-Layer Chromatography 2004
2004 Pharmacokinetics of Saquinavir plus Low-Dose Ritonavir in Human Immunodeficiency Virus-Infected Pregnant Women?Antimicrobial Agents and Chemotherapy.  48:430-436. 2004
2004 Effects of Concentration and Temperature on the Stability of Nevirapine in Whole Blood and Serum 2004
2003 HIV Protease Inhibitor Ritonavir Induces Lipoatrophy in Male MiceAIDS Research and Human Retroviruses.  19:1141-1150. 2003
2003 Duration of highly active antiretroviral therapy regimensClinical Infectious Diseases.  37:714-722. 2003
2003 Monitoring nevirapine-based programmes for prevention of mother-to-child transmission of HIV-1 [4] 2003
2003 Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapineAIDS.  17:1659-1665. 2003
2003 Intermittent administration of high-dose stavudine to nucleoside-experienced individuals infected with HIV-1 2003
2003 Analysis of Generic Nevirapine Products in Developing Countries [7]Journal of the American Medical Association.  289:2648-2649. 2003
2003 Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings 2003
2003 Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients 2003
2003 Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients. 2003
2003 Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography 2003
2003 Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virusClinical Infectious Diseases.  36:373-377. 2003
2003 Therapeutic drug monitoring in the treatment of HIV-infectionJournal of Clinical Virology.  27:117-128. 2003
2002 Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected childrenAntiviral Therapy.  7:267-270. 2002
2002 Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practiceAIDS Research and Human Retroviruses.  18:909-916. 2002
2002 Effect of Seville orange juice and grapefruit juice on indinavir pharmacokineticsJournal of Clinical Pharmacology.  42:1165-1170. 2002
2002 Durability of response to treatment among antiretroviral-experienced subjects: 48-Week results from AIDS Clinical Trials Group Protocol 359Journal of Infectious Diseases.  186:626-633. 2002
2002 The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (aids clinical trials group study 850)Journal of Infectious Diseases.  186:198-204. 2002
2002 Pharmacokinetic enhancement of protease inhibitors 2002
2002 Antiretroviral pharmacokinetics in the paediatric population: A reviewClinical Pharmacokinetics.  41:1115-1133. 2002
2002 Position paper on therapeutic drug monitoring of antiretroviral agentsAIDS Research and Human Retroviruses.  18:825-834. 2002
2001 Acyclovir for treatment of postherpetic neuralgia: Efficacy and pharmacokineticsAntimicrobial Agents and Chemotherapy.  45:2771-2774. 2001
2001 Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios 2001
2001 Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavirAntimicrobial Agents and Chemotherapy.  45:236-242. 2001
2001 Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinationsHIV Clinical Trials.  2:193-199. 2001
2001 Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS clinical trials group protocol 373Journal of Infectious Diseases.  183:715-721. 2001
2001 Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant womenHIV Clinical Trials.  2:460-465. 2001
2000 Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitorsClinical Infectious Diseases.  30. 2000
2000 Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patientsAIDS.  14:2869-2876. 2000
2000 Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884AIDS.  14:2495-2501. 2000
2000 Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: Results of adult AIDS clinical trials group protocol 370AIDS.  14:1553-1561. 2000
2000 Long-term stability of nelfinavir mesylate in human plasma [5] 2000
2000 Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcomaCancer Chemotherapy and Pharmacology.  46:173-179. 2000
2000 Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359Journal of Infectious Diseases.  182:1375-1384. 2000
1999 Indinavir concentrations and antiviral effect 1999
1999 Pharmacokinetic strategies for concentration-targeted therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV)Clinical Pharmacology and Therapeutics.  65:161. 1999
1998 Potential confusion with antiretroviral drugsAmerican Journal of Health-System Pharmacy.  55:2639-2640. 1998
1998 Concentration-controlled zidovudine therapyClinical Pharmacology and Therapeutics.  64:331-338. 1998
1997 Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy 1997
1997 ValacyclovirAnnals of Pharmacotherapy.  31:185-191. 1997
1996 Clinical Pharmacokinetics of Zidovudine: An UpdateClinical Pharmacokinetics.  30:251-262. 1996
1996 Disposition of zidovudine in obese pregnant women with human immunodeficiency virus type 1 infection [4]Journal of Infectious Diseases.  174:673. 1996
1996 Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDSAntimicrobial Agents and Chemotherapy.  40:2721-2726. 1996
1996 Hepatotoxicity and rash associated with zidovudine and zalcitabine chemoprophylaxis [2]ACP journal club.  124:855. 1996
1995 Antiretroviral drug interactionsInternational Journal of Antimicrobial Agents.  5:73-83. 1995
1995 Pentamidine Concentrations in a Mother with AIDS and in Her NeonateClinical Infectious Diseases.  20:1569-1570. 1995
1994 Agents for treating human immunodeficiency virus infectionAmerican Journal of Health-System Pharmacy.  51. 1994
1994 Gender differences in human pharmacokinetics and pharmacodynamicsJournal of Adolescent Health.  15:619-629. 1994
1993 Advances in pharmacotherapy: treatment of HIV infectionJournal of Clinical Pharmacy and Therapeutics.  18:375-388. 1993
1993 Leukotriene-receptor antagonists and 5-lipoxygenase inhibitors in asthmaAnnals of Pharmacotherapy.  27:898-903. 1993
1988 Thromboxane synthesis and actions in isolated adrenergic nerve (pheochromocytoma-12) cellsJournal of Pharmacology and Experimental Therapeutics.  247:43-46. 1988


Year Title Altmetric
2017 Antivirals (Nonretrovirals) 2017
2011 Antivirals (Nonretrovirals) 2011

Principal Investigator On

  • (IMPAACT) Subcontract BRS-IPHRM-S-08-00056, Equipment  awarded by SOCIAL & SCIENTIFIC SYSTEMS
  • A Multicenter, Open-Label, Noncomparative Study for the International Maternal, Pediatric, Adolescent AIDS Clinical Trials Group to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of MK-0518 in HIV-1 Infected Children (Study)  awarded by SOCIAL & SCIENTIFIC SYSTEMS
  • AIDS Clinical Trial Group (ACTG 5324) -- A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV  awarded by Brigham and Women's Hospital
  • AIDS Clinical Trials Group (ACTG)  awarded by University of California, Los Angeles
  • AIDS Clinical Trials Group Laboratory Center (ACTG)  awarded by University of California, Los Angeles
  • AIDS Clinical Trials Group Network (ACTG)  awarded by Brigham and Women's Hospital
  • AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections [ACTG LOC: Sp Lab A5324/A5345]  awarded by University of California, Los Angeles
  • Aids Clinical Trial Group: ACTG  awarded by Brigham and Women's Hospital
  • Anti-Viral Treatment in Mild Cognitive Impairment  awarded by RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. - NEW
  • Antiretroviral Quantitation and Modeling in the Female Genital Tract  awarded by Gates (Bill and Melinda) Foundation
  • IMPAACT 2019 - Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Disperible and Immediate Release Tablets in HIV-1-Infected Children less than 12 years of Age  awarded by Johns Hopkins University
  • IMPAACT 2023 –A Phase I Study of the Safety and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1  awarded by Johns Hopkins University
  • IMPAACT Network Lab PF Project Specific Task Order - Lab 12 (P1115)  awarded by Johns Hopkins University
  • International Maternal Medicine Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group Leadership (P1066)  awarded by Johns Hopkins University
  • International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group (P1093)  awarded by Johns Hopkins University
  • International Maternal Pediatric Adolescent AIDS Clinical Trails (IMPAACT) Group Leadership (P1110)  awarded by Johns Hopkins University
  • International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group  awarded by University of California, Los Angeles
  • International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group  awarded by Johns Hopkins University
  • International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group (P1097 and P1101)  awarded by Johns Hopkins University
  • International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group - P1097A LAB 05  awarded by Johns Hopkins University
  • International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group Leadership  awarded by Johns Hopkins University
  • International Maternal Pediatric Adolescent AIDS Clinical Trials Group ("IMPAACT")  awarded by SOCIAL & SCIENTIFIC SYSTEMS
  • International Maternal Pediatric Adolescent AIDS Clinical Trials Group ("IMPAACT")  awarded by SOCIAL & SCIENTIFIC SYSTEMS
  • International Maternal Pediatric Adolescent AIDS Clinical Trials Group -- Lab 11  awarded by Johns Hopkins University
  • International Maternal Pediatric Adolescent AIDS Clinical Trials Group Leadership (ARRA Administrative Supplement)  awarded by SOCIAL & SCIENTIFIC SYSTEMS
  • International Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network (IMPAACT LC)  awarded by University of California, Los Angeles
  • Laboratory Center - IMPAACT Leadership Group  awarded by Childrens Hospital Los Angeles
  • Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/  awarded by University of California, Los Angeles
  • Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/ [Specialty Lab Fixed Rate]  awarded by University of California, Los Angeles
  • Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/[PF Spec. Lab]  awarded by University of California, Los Angeles
  • Long Acting Self Administered HIV Therapy with CCR5 Antibody PRO 140  awarded by Drexel University College of Medicine
  • Predictors of Treatment Toxicity, Failure, and Relapse in HIV-related Tuberculosis  awarded by VANDERBILT UNIVERSITY
  • Private Grant  awarded by ACTUACTED MEDICAL INC
  • Private Grant  awarded by ACTUACTED MEDICAL INC
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY
  • UAB ACTG Pharmacology Support Laboratory  awarded by SOCIAL & SCIENTIFIC SYSTEMS
  • UAB IMPAACT Pharmacology Support Laboratory  awarded by SOCIAL & SCIENTIFIC SYSTEMS
  • Education And Training

  • Doctor of Pharmacy in Pharmacy, Pharmaceutical Sciences, and Administration, University of Minnesota System : Twin Cities 1992
  • Full Name

  • Edward Acosta